The - 250G→A polymorphism in the human hepatic lipase gene promoter affects blood lipids in Chinese
Shuiping Zhao,Xiangzhu Xie,Sai Nie
DOI: https://doi.org/10.1016/j.cca.2005.08.013
IF: 6.314
2006-01-01
Clinica Chimica Acta
Abstract:Background Human hepatic lipase (HL) is a glycoprotein that catalyzes the hydrolysis of triglycerides and phospholipids in all major classes of lipoproteins. We studied whether the hepatic lipase gene − 250G(guanine)→A(adenine) polymorphism affect blood lipids level and the coronary heart disease. Methods Two hundred and thirty subjects were included. Among them there were 122 patients with coronary heart disease and 108 subjects without coronary heart disease. Polymerase chain reaction-restricted fragments length polymorphism was used to determine HL genotype. Results The serum HDL-C level of HL-250A heterozygote (carriers of GA genotype) and homozygote (carriers of AA genotype) [(1.32 ± 0.35) mmol/l] was significantly higher than wild type [carriers of GG genotype, (1.19 ± 0.30) mmol/l, P < 0.005]. This effect to blood lipids appears more evident in women ( P < 0.005). But the distribution of the 3 genotypes of HL-250 among the patients with coronary heart disease (GG54.1%, GA37.7%, AA8.2%) were similar with those of the control (GG54.6%, GA37.0%, AA8.4%, P > 0.05). Both the male and the female had similar ratio for 3 HL genotypes. Conclusions HL-250G→A variation affects blood lipids profile and results in the increasing of the serum HDL-C level. This beneficial effect to blood lipids profile is more obviously seen in the female. Keywords Hepatic lipase gene Single nucleotide polymorphism (SNP) High density lipoprotein (HDL) Coronary heart disease (CHD) Gender 1 Introduction Hepatic lipase (HL) is a lipolytic enzyme that hydrolyzes triglycerides (TG) and phospholipids on plasma lipoproteins. It also plays a role as a ligand mediating the binding and uptake of lipoproteins via proteoglycans and/or receptor pathways. Thus, both lipolytic and nonlipolytic functions of HL are important for HDL metabolism and ultimately to its association with CHD risk. Recent studies have identified 4 common polymorphisms in the HL gene promoter, such as − 250G→A, − 514C→T, − 710T→C, − 763A→G. Association on the alleles of the HL gene with the concentration of serum lipoproteins and the coronary heart disease (CHD) have been investigated thoroughly, but little is known about this in Chinese. We studied the − 250G→A variation in 230 Chinese Hans which accounts for 95% of the Chinese population and test the relationships between the − 250G→A variation and the coronary heart disease or plasma HDL cholesterol concentration. 2 Materials and methods 2.1 Subjects One hundred and twenty-two patients with CHD were from the Second Xiangya Hospital of Central South University from March, 2003 to March, 2004. All of them were examined by coronary angiography using the Judkins technique. For the coronary score, main coronary artery branches (left anterior descending, left circumflex artery, or right coronary artery) having at least 1 stenosis of ≥ 70% were recorded. Among them, there were 24 patients of acute myocardium infarction, 41 patients of unstable angina pectoris, and 57 patients of stable angina pectoris and old myocardium infarction. Meanwhile, 108 unrelated age-matched subjects selected via health-screening at the same hospital free of any clinical and biochemical signs of CHD were used as controls for the study. Among all the 230 subjects, there were 144 males and 86 females, and the mean age was 53(25∼89) y. Subjects with peripherial vessel diseases or peripherial vessel embolism diseases, stroke, severe liver or renal dysfunction, thyroid diseases, diabetes, or used lipid-lowering agents before hospitalization were excluded. 2.2 Methods 2.2.1 DNA preparation Genomic DNA was prepared from peripheral blood leukocytes using the “salting-out” procedure and stored at 4 °C. 2.2.2 Hepatic lipase - 250 genotype testing A G-to-A substitution at 250bp upstream of the transcription initiation site created an Dra I restriction site (5′-TTT↓AAA-3′). To assay the polymorphism, a 327-bp fragment containing the restriction site was PCR-amplified using the forward primer 5′-CCT ACC CCG ACC TTT GGC AG-3′ and the reverse primer 5′-GGG GTC CAG GCT TTC TTG G-3′.An initial denaturation step at 94 °C for 3 min was followed by 32 cycles of 94 °C for 50 s, 64 °C for 50 s, and 72 °C for 1 min, and a final extension step of 10 min at 72 °C. Each PCR amplification mixture contained 0.1∼0.3 μg genomic DNA, 5 pmol of each primer, 2.5 nmol dNTPs and standard PCR buffer in a total volume of 10 μl. A PCR product was digested with the restriction enzyme DraI recognizing the−250A mutation and an internal control site on 37 °C for 16 h. The fragments were analyzed by electrophoresis on a 5% polyacrylamide gel. 2.2.3 Measurement of lipids and lipoproteins Blood samples were collected at baseline from patients and controls after an overnight fast. Indexes were measured containing the plasma levels of total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), liver and renal function and fasting plasma glucose, etc. 2.2.4 Statistical analysis Statistical analysis was performed using SPSS 12.0. A p value < 0.05 on a 2-sided test was significant. The lipid phenotypic data between the CHD patients and controls were age and gender adjusted. Major statistical indexes were under normal inspection. Normal distributed indexes were indicated with mean ± standard deviation ( x¯ ± SD ). Comparison of measurement data between groups were analyzed by indepent-samples t test. Comparison among several samples were analyzed by one-way ANOVA test, LSD method. Comparison of classification data between groups were analyzed by χ 2 test. 3 Results 3.1 Biochemical indexes ( Table 1 ) Plasma biochemical indexes levels were compared between CHD and control groups. As shown in Table 1 , the parameters used for HDL-C, TG/HDL-C and FBS were significantly different between the 2 groups ( P < 0.05). 3.2 Association between G→A substitution and plasma lipids ( Tables 2 and 3 ) Studies on the relation between G→A ( HL -250) and plasma lipid showed that neither cholesterol, triglyceride, nor LDL-C was different significantly between subjects with or without this gene variant. However, HDL-C levels did differ among different genotypes ( P < 0.05) ( Tables 2 and 3 ). 3.3 Association between G→A substitution and plasma lipids on gender ( Table 4 ) The effect of HL genotype to blood lipids appeared more evident in women. In the female, the level of HDL-C was significant higher in carriers of GA + AA genotype than in carriers of GG genotype, which was not seen in the male. We screened the distribution of the G→A in the males and the females too. No deviation of the distribution was noted in both the males and the females ( χ 2 = 0.912, P = NS) ( Table 4 ). 3.4 Distribution of the G→A( HL -250) in CHD patients and controls To determine the prevalence of the G→A substitution, we analyzed this variation in all the 122 CAD patients and 108 controls. The distribution of the 3 genotypes of HL-250 among the group of coronary heart disease patients (GG54.1%, GA37.7%, AA8.2%) were similar with that of the control group (GG54.6%, GA37.0%, AA8.4%; χ 2 = 0.011, P = NS) after correction for gender and BMI. 4 Discussion Hepatic lipase (HL) gene polymorphisms have attracted considerable interest because they affect total HDL-C levels, especially HDL 2 -C [1–6] . In present study, we show that HDL-C level of the − 250GA or AA carriers was obviously higher than that of GG carriers. The − 250A allele brings beneficial effect to Chinese Hans, too. There is considerable evidence that hepatic lipase activity is an important determinant of plasma HDL-C concentrations [9,10] . Clinical studies have consistently found an inverse relationship between HL activity measured in post heparin plasma and HDL-C concentrations. Therefore, it seems very likely that the − 250A allele increasing HDL-C level is associated with low HL activity by directly affecting HL expression or through linkage disequilibrium with another polymorphism that directly decrease the enzyme activity. Epidemiologic studies have revealed that a low plasma concentration of HDL-C is a major independent risk factor for coronary heart disease [7,8] . Nevertheless, though HDL-C level is markedly different between the − 250A carriers and the other, − 250A allele has no obvious influence on the episode of CHD in our study. The explanations to this are not distinct yet: (1) HL influents the function of HDL: HL executes crucial functions in the process of reverse cholesterol transport from the periphery to the liver. Thus, HL increases the formation of nascent, pre-β HDL particles that mediate cholesterol efflux and enhances the selective cholesteryl ester uptake from HDL to the liver via the HDL receptor SR-B1 [11] . (2)−250A allele is associated with decrease of the plasma level of small, dense LDL [1] . (3) Perhaps our sample size is too small. So, with comprehensive analysis, we deduce that the influence of HL-250 gene polymorphism to CHD may be decided by the change of plasma HDL-C level, extent of reverse cholesterol transport and small, dense LDL level. Meanwhile, De Andrade et al. [6] observed that HL-250A allele only has beneficial lipids effect to men, but not to women. But our study showed that the effect to blood lipids of HL-250A allele appears more evident in women. It is established that the HL activity is lower in premenopause women than in men [12,13] . And estrogen replacement therapy to postmenopause women may change HL activity and result in the increasing of HDL 2 -C level [14,15] . Estrogen decrease post-heparin plasma HL activity and the effect is associated with decreased HL mRNA. Estrogen repress the transcription of the HL gene through a mechanism that estrogen receptor-α (ERα) interact with an AP-1 binding motif in − 1557/− 1175 of the HL promoter [16] . Despres et al. showed that intra-abdominal fat (IAF) content is strongly correlated with HL activity and that this association is independent of the effect of total body adiposity [17] . Premenopausal women have less IAF than men [18] , and the HL gene promoter − 250A allele attenuates the increase in HL activity due to IAF in premenopausal women [19] . Therefore, the synthetic action of HL gene polymorphism, estrogen and IAF may make a relatively higher increasing of plasma HDL-C level. In summary, we identified that the association between HL-250G→A variation and HDL-C concentration is significant. It suggests that genetic variation at the HL locus is involved in the determination of lipid and lipoprotein profile. In addition, the effect appears more evident in women. References [1] A. Zambon S.S. Deeb J.E. Hokanson Common variants in the promoter of the hepatic lipase gene are associated with lower levels of hepatic lipase activity,buoyant LDL,and higher HDL 2 cholesterol Arterioscler Thromb Vasc Biol 18 1998 1723 1729 [2] J.C. Cohen C.L. Vega S.M. Grudy Hepatic lipase: new insights from genetic and metabolic studies Curr Opin Lipidol 10 1999 259 267 [3] R. Guerra J. Wang S.M. Grundy A hepatic lipase (LIPC) allele associated with high plasma concentrations of high density lipoprotein cholesterol Proc Natl Acad Sci U S A 94 1997 532 537 [4] S. Murtomaki E. Tahvanianen M. Antikainen Hepatic lipase gene polymorphism influence plasma HDL levels: results from Finish EARS participants Arterioscler Thromb Vasc Biol 17 1997 879 884 [5] K.W. Park J.H. Choi I.H. Chae Hepatic lipase C514T polymorphism and its relationship with plasma HDL-C levels and coronary artery disease in Koreans J Biochem Mol Biol 36 2003 237 242 [6] F.M. de Andrade F.R. Silveira M. Arsand Association between−250G/A polymorphism of the hepatic lipase gene promoter and coronary artery disease and HDL-C levels in a Southern Brazilian population Clin Genet 65 2004 390 395 [7] G. Lambert M.J. Amar P. Martin Hepatic lipase deficiency decreases the selective uptake of HDL-cholesteryl esters in vivo J Lipid Res 41 2000 667 672 [8] T. Thuren Hepatic lipase and HDL metabolism Curr Opin Lipidol 11 2000 277 283 [9] T. Gordon W.P. Castelli M.C. Hjortland High density lipoproteins as a protective factor against coronary heart disease. The Framinghan Study Am J Med 62 1977 707 714 [10] U. Goldbourt S. Yaari J.H. Medalie Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality: a 21-year follow up of 8000 men Arterioscler Thromb Vasc Biol 17 1997 107 113 [11] K.A. Dugi K. Brandauer N. Schmidt Low hepatic activity is a novel risk factor for coronary artery disease Circulation 104 2001 3057 3062 [12] M.C. Carr J.E. Hokanson A. Zambon The contribution of intraabdominal fat to gender differences in hepatic lipase activity and low/high density lipoprotein heterogeneity J Clin Endocrinol Metab 86 2001 2831 2837 [13] S.S. Deeb A. Zambon M.C. Carr Hepatic lipase and dyslipidemia: interactions among genetic variants, obesity, gender, and diet J Lipid Res 44 2003 1279 1286 [14] Y. Somekawa H. Umeki K. Kobayashi Effects of hormone replacement therapy and hepatic lipase polymorphism on serum lipid profiles in postmenopausal Japanese women J Clin Endocrinol Metab 87 2002 4766 4770 [15] K. Yamakawa-Kobayashi Y. Somekawa M. Fujimura Relation of the − 514C/T polymorphism in the hepatic lipase gene to serum HDL and LDL cholesterol levels in postmenopausal women under hormone replacement therapy Atherosclerosis 162 2002 17 21 [16] D.R. Jones R.J. Schmid R.T. Pickard Estrogen receptor-mediated repression of human hepatic lipase gene transciption J Lipid Res 43 2002 383 391 [17] J.P. Despres M. Ferland S. Moorjani Role of hepatic-triglyceride lipase activity in the association between intra-abdominal fat and plasma HDL cholesterol in obese women Arteriosclerosis 9 1989 485 492 [18] S. Lemieux D. Prudhomme C. Bouchard Sex differences in the relation of visceral adipose tissue accumulation to total body fatness Am J Clin Nutr 58 1993 463 467 [19] M.C. Carr J.E. Hokanson S.S. Deeb A hepatic lipase gene promoter polymorphism attenuates the increase in hepatic lipase activity with increasing intra-abdominal fat in women Arterioscler Thromb Vasc Biol 19 1999 2701 2707